Jasmine Sun

Jasmine Sun appears in The ‘biohacking’ trend that has tech workers experimenting on themselves as the independent technology journalist whose [[NewYorkTimes|New York Times]] reporting grounds Marketplace Tech’s episode on Silicon Valley peptide use. Her interview connects cheaper GLP-1 Agonists, Ozempic demand, research-chemical labeling, Chinese peptide suppliers, and founder-style risk tolerance into a single Tech-Culture Biohacking story.

Her contribution is mainly explanatory. She distinguishes legal permissibility from medical assurance: a substance may be outside the DEA-controlled-drug list while still lacking [[FoodAndDrugAdministration|FDA]] approval, known contents, clean manufacturing standards, human clinical evidence, or safe dosing context.

Connections

• Marketplace Tech - show that interviews her.
• [[NewYorkTimes|New York Times]] - publication context for the underlying reporting.
• Gray-Market Peptides, Research Chemical Loophole, and GLP-1 Agonists - main topics she explains.
• Tech-Culture Biohacking and Self-Experimentation - cultural and behavioral frame she gives the trend.